

PATENT
Customer No. 22,852
Attorney Docket No. 02481.1768

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Marc NAZARÉ et al.) Group Art Unit: 1624
Serial No.: 10/023,933) Examiner: R. Raymond
Filed: December 21, 2001)
For: NEW OXYBENZAMIDE)
DERIVATIVES USEFUL FOR)
INHIBITING FACTOR XA OR VIIA)

RECEIVED

DEC 02 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TECH CENTER 1600/2900

Sir:

RESPONSE TO OFFICE ACTION

This paper responds to the Office Action mailed September 26, 2003, which set a shortened statutory period for response of one month. In a separate Petition, Applicants have requested and paid the fee for a one-month extension of time. Thus, this response is timely filed by November 26, 2003.

REMARKS

In the Office Action, the Examiner asserts that claim 1 is generic to a plurality of patentably distinct species comprising the compounds of the working examples. Office Action, page 2. Applicants are required to elect a single species for examination. The Examiner notes that related compounds will then be grouped together for examination purposes. In response, Applicants elect the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com